Lars Hanker

5.3k total citations
100 papers, 2.4k citations indexed

About

Lars Hanker is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology. According to data from OpenAlex, Lars Hanker has authored 100 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Reproductive Medicine, 35 papers in Obstetrics and Gynecology and 32 papers in Oncology. Recurrent topics in Lars Hanker's work include Ovarian cancer diagnosis and treatment (44 papers), Endometrial and Cervical Cancer Treatments (29 papers) and Intraperitoneal and Appendiceal Malignancies (11 papers). Lars Hanker is often cited by papers focused on Ovarian cancer diagnosis and treatment (44 papers), Endometrial and Cervical Cancer Treatments (29 papers) and Intraperitoneal and Appendiceal Malignancies (11 papers). Lars Hanker collaborates with scholars based in Germany, United States and Italy. Lars Hanker's co-authors include Achim Rody, Uwe Holtrich, Thomas Karn, Manfred Kaufmann, Dirk Metzler, Christine Solbach, A. Ahr, Cornelia Liedtke, R. Gaetje and Jalid Sehouli and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Lars Hanker

90 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Hanker Germany	25	1.0k	827	724	513	364	100	2.4k
Ricardo R. Lastra United States	21	1.1k 1.0×	1.2k 1.4×	552 0.8×	781 1.5×	355 1.0×	76	3.1k
Rebecca Kristeleit United Kingdom	27	1.6k 1.6×	1.4k 1.7×	711 1.0×	400 0.8×	160 0.4×	147	2.9k
Volker Möbus Germany	26	1.2k 1.1×	493 0.6×	422 0.6×	587 1.1×	231 0.6×	117	2.2k
Jean‐Sébastien Frenel France	26	1.4k 1.3×	801 1.0×	295 0.4×	708 1.4×	284 0.8×	188	2.7k
Renaud Sabatier France	24	1.4k 1.3×	675 0.8×	282 0.4×	645 1.3×	158 0.4×	129	2.5k
Giorgio Valabrega Italy	28	1.8k 1.8×	946 1.1×	394 0.5×	497 1.0×	136 0.4×	115	2.8k
Frauke Bentzien United States	10	665 0.6×	821 1.0×	288 0.4×	298 0.6×	126 0.3×	12	2.1k
Michael S. Anglesio Canada	32	652 0.6×	1.5k 1.8×	1.8k 2.5×	737 1.4×	300 0.8×	71	3.6k
Ingunn M. Stefansson Norway	36	1.5k 1.4×	2.2k 2.7×	625 0.9×	1.3k 2.6×	177 0.5×	73	4.4k
David N. Church United Kingdom	28	1.7k 1.6×	1.1k 1.3×	1.0k 1.4×	1.3k 2.5×	353 1.0×	75	4.4k

Countries citing papers authored by Lars Hanker

Since Specialization

Citations

This map shows the geographic impact of Lars Hanker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Hanker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Hanker more than expected).

Fields of papers citing papers by Lars Hanker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Hanker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Hanker. The network helps show where Lars Hanker may publish in the future.

Co-authorship network of co-authors of Lars Hanker

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Hanker. A scholar is included among the top collaborators of Lars Hanker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Hanker. Lars Hanker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Köster, Frank, Karen Bräutigam, Achim Rody, et al.. (2025). Prognostic and clinical heterogeneity of PD1 and PD-L1- immunohistochemical scores in endometrial cancers. Archives of Gynecology and Obstetrics. 311(5). 1395–1405.

Wimberger, Pauline, Jacobus Pfisterer, Andreas du Bois, et al.. (2025). Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group – Real-world observations. European Journal of Surgical Oncology. 51(6). 109696–109696.

Ghamande, Sharad, Lars Hanker, Destin Black, et al.. (2024). Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Gynecologic Oncology. 190. S6–S6. 11 indexed citations

Krell, Jonathan, John McGrane, Andreas D. Hartkopf, et al.. (2024). Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression. Future Oncology. 20(40). 3409–3419. 1 indexed citations

Mirza, Mansoor Raza, Sudarshan Sharma, Jørn Herrstedt, et al.. (2023). 740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S507–S507. 20 indexed citations

Chase, Dana M., Line Bjørge, Robert L. Coleman, et al.. (2023). #267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial. A8–A9. 2 indexed citations

Mirza, Mansoor Raza, Dana M. Chase, Brian M. Slomovitz, et al.. (2023). Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11). Gynecologic Oncology. 176. S43–S44. 2 indexed citations

Wimberger, Pauline, Jacobus Pfisterer, Andreas du Bois, et al.. (2023). Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group. International Journal of Gynecological Cancer. 33(7). 1083–1089. 6 indexed citations

Graspeuntner, Simon, Jennifer Herrmann, Katharina Rox, et al.. (2023). Sorangicin A Is Active against Chlamydia in Cell Culture, Explanted Fallopian Tubes, and Topical In Vivo Treatment. Antibiotics. 12(5). 795–795. 1 indexed citations

10.

Krell, Jonathan, John McGrane, Anjana Anand, et al.. (2022). 2022-RA-1505-ESGO Ovarian cancer retrospective European (O’CaRE) observational study: analysis of first-line (1L) outcomes in patients with ovarian cancer (OC) stratified by number of risk factors for progression. International Journal of Gynecological Cancer. 32. A344–A344. 1 indexed citations

11.

Hanker, Lars, Ahmed El‐Balat, Stefan Kommoss, et al.. (2021). Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer. Journal of Cancer Research and Clinical Oncology. 147(5). 1421–1430. 2 indexed citations

12.

Hanker, Lars, Frank Förster, Andrea Gräfe, et al.. (2020). Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer. Anticancer Research. 40(7). 3973–3981. 5 indexed citations

13.

Baumann, Klaus, Andreas du Bois, Werner Meier, et al.. (2012). A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Annals of Oncology. 23(9). 2265–2271. 67 indexed citations

14.

Karn, Thomas, Lajos Pusztai, Eugen Ruckhäberle, et al.. (2011). Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. European Journal of Cancer. 48(1). 12–23. 39 indexed citations

15.

Hanker, Lars, Thomas Karn, Eugen Ruckhäberle, et al.. (2010). SATB1 gene expression and breast cancer prognosis. The Breast. 20(4). 309–313. 38 indexed citations

16.

Ruckhäberle, Eugen, Thomas Karn, Lars Hanker, et al.. (2010). Breast Cancer Proteomics – Differences in Protein Expression between Estrogen Receptor-Positive and -Negative Tumors Identified by Tandem Mass Tag Technology. Breast Care. 5(1). 7–10. 5 indexed citations

17.

Rody, Achim, Uwe Holtrich, L. Pusztai, et al.. (2009). T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Research. 11(2). R15–R15. 336 indexed citations

18.

Ruckhäberle, Eugen, Thomas Karn, Achim Rody, et al.. (2009). Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. Journal of Cancer Research and Clinical Oncology. 135(8). 1005–1013. 84 indexed citations

19.

Engels, Knut, Shirley K. Knauer, Sibylle Loibl, et al.. (2008). NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas. Cancer Research. 68(13). 5159–5166. 64 indexed citations

20.

Ruckhäberle, Eugen, Thomas Karn, Lars Hanker, et al.. (2008). Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. Journal of Cancer Research and Clinical Oncology. 135(1). 81–90. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact